Successful storage of RBCs for 10 weeks in a new additive solution

Current blood storage practices face limitations in shelf life, affecting availability and reducing the efficiency of transfusion programs. Standard additive solutions allow for up to 6 weeks of storage, but this duration is insufficient for some clinical and logistical needs. Prior research has shown that extending the storage period can help reduce the outdating of blood units and improve access in remote areas. However, the effects of longer storage on red blood cell (RBC) quality remain unclear. No prior work had resolved whether an alkaline additive solution could maintain RBC integrity over 10 weeks. This uncertainty drove the need to test a new solution for its potential to extend storage time while preserving RBC function. Understanding the impact of storage duration on RBC parameters is essential for optimizing transfusion safety and availability. The study aimed to bridge this knowledge gap by evaluating a novel additive solution. The findings could help refine storage protocols and improve transfusion outcomes. This research contributes to the ongoing effort to enhance blood bank efficiency and patient care.

The study aimed to assess the viability of storing RBCs in a new experimental additive solution for 10 weeks. The researchers wanted to determine whether this solution could maintain RBC quality over an extended period compared to a standard solution. They focused on parameters such as in vivo recovery, ATP levels, hemolysis, and morphological changes. The motivation was to find a solution that could reduce the outdating of blood units and support transfusion needs in remote locations. The researchers also sought to evaluate the impact of WBC reduction on storage outcomes. They compared the new solution with AS-1, a commonly used additive solution. The study was designed to provide evidence for potential changes in blood storage guidelines. This approach could improve the efficiency of autologous donor programs and transfusion logistics.

The researchers used packed RBCs collected from healthy donors and suspended them in 300 mL of EAS 64, an alkaline experimental additive solution. The RBC units were WBC reduced and stored for 10 weeks under standard blood bank conditions. For comparison, non-WBC-reduced units from the same donors were stored in AS-1 for 6 weeks. In vitro assays were conducted using standard methods to assess RBC quality. In vivo recovery was measured using (51)Cr- and (99m)Tc-labeled RBCs. The study tracked ATP levels, hemolysis rates, supernatant potassium concentrations, and morphological indices. The experimental design allowed for a direct comparison between the two storage solutions. The researchers ensured that all measurements were taken at consistent intervals to evaluate changes over time.

After 10 weeks of storage in EAS 64, the mean in vivo recovery of RBCs was 84 ± 8 percent, matching the recovery rate of AS-1 units stored for 6 weeks. ATP levels in EAS 64 units remained at 85 percent of the initial value, compared to 64 percent in AS-1 units. Hemolysis was 0.43 percent in EAS 64 units and 0.63 percent in AS-1 units. Supernatant potassium levels were 24 mEq per L in EAS 64 units and 44 mEq per L in AS-1 units. The morphologic index for EAS 64 units was 98, while it was 71 for AS-1 units. These results suggest that EAS 64 maintains RBC quality over a longer storage period. The lower potassium levels in EAS 64 units indicate reduced cell damage. The higher ATP levels in EAS 64 units suggest better metabolic preservation.

The study found that RBCs suspended in EAS 64 can be stored for 10 weeks without significant loss of function or integrity. The in vivo recovery rates were comparable to those of AS-1 units stored for 6 weeks. ATP levels in EAS 64 units were higher than in AS-1 units, suggesting better metabolic preservation. Hemolysis and potassium levels were lower in EAS 64 units, indicating less cell damage. The morphologic index was higher in EAS 64 units, supporting the conclusion that the new solution preserves RBC structure. The authors propose that longer storage times could reduce outdating and improve transfusion availability. The findings suggest that EAS 64 may be a viable alternative to current additive solutions. The study supports the potential for extending RBC storage periods in clinical practice.